Tedopi is the Company's Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi to chemotherapy in non-small cell lung cancer
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
OSE Immunotherapeutics SA: Four Poster Presentations at 2022 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.